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Abstract: In this study we investigated nitric
oxide metabolites nitrate+nitrite and lipid
peroxidation product (malonyldialdehyde:
MDA) related to the pathogenesis of eclampsia
and intrauterine growth retarded (IUGR)
pregnancy.
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Plasma nitrate+nitrite levels were higher in
the eclamptic (31.6 ± 16.7 µmol/L p < 0.001)
and IUGR (24.3 ± 9.5 µmol/L p < 0.005)
groups than in the control group (18.8 ± 6.9
µmol /L). Plasma MDA levels were higher in
the eclamptic group (5.5 ± 2.5 nmol/ml (p <
0.05) but not significantly different in the

Introduction
Eclampsia is a multisystemic disorder the aetiology of
which is still unknown. There is increasing evidence that
altered endothelial cell functions play an important role in
the pathogenesis of pre-eclampsia and eclampsia (1).

IUGR (3.4 ± 2.4 nmol/ml p > 0.05) group
than control group (3.0 ± 1.3 nmol/ml). In
addition, the plasma nitrite+nitrate and MDA
levels in the eclamptic group were higher
than in the IUGR group (p < 0.05).
These variations could play different roles in
the pathogenesis of eclampsia and IUGR
pregnancy.
Key Words: Eclampsia, IUGR, nitric oxide,
lipid peroxidation

endovascular trophoblast and endothelial cells (12). Some
reports indicate that blood levels of lipid peroxidation
products (Malonyldialdehyde: MDA) are elevated in preeclamptic pregnancy and it has been suggested that these
play a role in the aetiology of the disease (12,13).

An intrauterine growth retarded (IUGR) infant is
commonly defined as one weighting less than the 10th
percentile in birth weight for its gestational age. Such
infants are also at a higher risk of perinatal morbidity and
mortality, the risk rising with the severity of the growth
restriction (2). Evaluations of blood flow velocity
waveforms by Doppler ultrasound have shown that 20%
to 88% of cases of IUGR are associated with increased
vascular resistance in the foetoplacental circulation (3).

We have encountered no studies concerning NO
metabolites nitrite+nitrate and lipid peroxidation product
in the same cases with eclamptic and IUGR pregnancy.

Nitric oxide (NO) is a potent vasodilator agent which
modulates pulmonary and systemic vascular tone (4). In
our previous study, we found low NO levels in patients
with pulmonary hypertension and congenital heart
defects (5). Altered production of NO by the vascular
endothelium may influence the pathogenesis of preeclampsia (6). Relative to normal pregnancy there have
been reports of either a decrease (7), an increase (8,9) or
no change (10,11) in NO levels in pre-eclampsia.

Materials and Methods

Oxygen free radicals are extremely reactive molecules
and might form the link between the injury of the

Nitrite+nitrate levels were determined by the Griess
reaction, which relies on a colorimetric reaction between

The aim of this study was to investigate MDA and
nitrite+nitrate concentrations in the plasma in normal,
eclamptic and IUGR pregnacies and to determine the
parameters which may contribute to the pathophysiology
of these cases.

With the approval of the local ethics committee
patients and controls in the third trimester were selected
at the Zekai Tahir Burak Women’s Health Training and
Research Hospital. Peripheral venous blood specimens
were collected into tubes with EDTA. Samples were
centrifuged at 3000 rpm for 15 min and the plasma
removed from each sample.
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nitrite,
sulphanilamide
and
N-(1-naphthyl)
ethylenediamine dihydrochloride to produce a pink Azo
product. Prior to the Griess reaction all nitrate was
converted to nitrite using bacterial enzyme nitrate
reductase. Concentrations were determined by
comparison to a standard solution of sodium nitrite (14).

Furthermore, plasma nitrite+nitrate levels in
eclamptic patients were higher than in IUGR patients (p <
0.05). In our study there was no correlation between the
parameters of the groups.

Discussion

Plasma MDA assays were performed according to
Hunter et al. (15).

In this study we found higher plasma MDA levels in
the eclamptic group than in the control group and IUGR
group (p < 0.05). There were no significant differences
between the IUGR and control groups.

All data were expressed as the mean value ± SD.
Statistical analysis was performed with a determination
of the correlation coefficient and comparison between
groups by Student’s t-test and the Kruskal Wallis analysis
of variance test. Differences of p < 0.05 were considered
significant.

The results of Wang et al. (16) showed that
pregnancy creates oxidative stress and increased stress
levels in pre-eclampsia. Vasoconstriction was the main
pathophysiological defect in pre-eclampsia. In addition,
endothelial cell damage and related protein increased
sensitivity to vasopressor substances. Functional defects
in the cell membrane are other pathophysiological
changes caused by lipid free radicals and lipid peroxides.
It has been claimed that oxygen free radicals and lipid
peroxides disturb NO formation in endothelial cells (17).

Results
Table 1 summarises the clinical parameters of the
groups included in this study.
Plasma nitrite+nitrate and MDA levels of the patient
and control groups are given in Table 2 and the Figure.

We have encountered no studies concerning plasma
nitrite+nitrate levels in eclampsia. There have been
studies which suggested that endothelial changes in preeclampsia pathophysiology might be related to either an
increase or a decrease in the synthesis of NO. Some
researchers found high nitrite+nitrate levels of plasma in

Eclamptic patients had higher plasma nitrite+nitrate
(p < 0.001) and MDA levels (p < 0.005) than the
controls. Only the plasma nitrite+nitrate levels were high
in IUGR patients (p < 0.05), and the MDA levels were not
significantly different to the control group.

Table 1. Clinical and chemical parameters of the groups.
Eclampsia
(n = 15)

Control
(n = 31)

Primigravida

75%

50%

48%

Age (years)

24.5 ± 5.0

24.9 ± 5.2

24.8 ± 4.23

Gestation at sampling (weeks)

34 ± 1.7

36 ± 1.9

36.6 ± 1.5

Gestation at delivery (weeks)

34 ± 1.9

37 ± 1.6

38 ± 1.76

2064 ± 395

2190 ± 167

3354 ± 320

162 ± 25

135 ± 25

109 ± 8

Infant birthweight (g)
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)

108 ± 20

90 ± 19

67 ± 9

Haemoglobin (g/dl)

12.7 ± 1.2

12.3 ± 1.0

12.4 ± 1.4

Urea (mg/dl)

31 ± 12

21 ± 11

20 ± 4

Creatinine (mg/dl)

1.0 ± 0.2

0.7 ± 0.2

0.8 ± 0.1

Proteinuria (mg/dl)

930 ± 56

232 ± 99

----

The data are shown as mean ± SD values or as percentages.
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(n = 17)
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Table 2. Plasma nitrite+nitrate, MDA levels of patients and controls.

Nitrite + nitrate (µmol/L)
MDA (nmol/ml)

Eclampsia (n = 15)

IUGR (n = 17)

Control (n = 31)

31.6 ± 16.7a
5.5 ± 2.5d

24.3 ± 9.5b,c
3.4 ± 2.4c

18.8 ± 6.9
3.0 ± 1.3

The data are shown as mean ± SD values. a p < 0.001 compared to control group, b p < 0.05
compared to control group, c p < 0.05 compared to eclamptic group, d p < 0.05 compared to
control group.
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Figure. Plasma nitrite+nitrate, MDA levels in patients and controls.

pre-eclamptic patients compared to normal pregnacies
(8,18).
Norris et al. (19) found high NO levels in the
uteroplacental, foetoplacental and peripheral circulations
in pre-eclamptic pregnancies. Zeeman et al. (20)
suggested that high lipid peroxides lowered vascular
prostocycline and NO release in uteroplacental vascular
region. Pinto et al. (17) found low NO release in umbilical
vessel endothelial cells in pre-eclamptic patients. On the
other hand, some researchers have not detected any
difference in plasma NO levels between pre-eclamptic and
normal pregnancies (9,14). This finding could have
several explanations. Nitrite+nitrate levels are altered by
renal function. However, our results showed that serum
creatinine was not high in the patient groups and did not
correlate with nitrite+nitrate levels. Furthermore,
gestational ages at sampling and the severity of the
disease may be another factor in pre-eclamptic and
eclamptic studies. The authors observed some alterations
in NO levels between different gestational ages in normal
pregnancy (20). Our significantly high levels of plasma
nitrite+nitrate might be due to the clinical progress of
eclampsia being more severe than pre-eclampsia.

Furthermore we thought that the factors which maintain
endothelial function might be kept in balance in the early
stages of the disease, but that this balance might be
damaged in the further stages of eclampsia.
IUGR, because of the variety of its mechanisms, is a
complicated clinical occurrence, which requires new
developments and research in diagnosis and therapy (21).
Although placental pathology as a factor in IUGR
remains to be fully elucidated, there is agreement that
altered uteroplacental haemodynamics are important in
the pathophysiology of the problem. Due to the
vasodilator effects of NO on the placental vasculature, an
impairment in NO production has been proposed as a
possible mechanism for reducing foetoplacental
circulation in pregnancy complications associated with
vasospasm, such as pre-eclampsia and/or IUGR (6,19).
In our study, plasma nitrite+nitrate levels were
significantly higher in the IUGR group than in the control
group (p < 0.05). We found a significant difference
between eclampsia and IUGR (p < 0.05) for plasma
nitrite+nitrate levels. We found no marked differences in
plasma MDA levels in the IUGR group compared to the
control group (p > 0.05).
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These results show that plasma NO and MDA levels
may possibly be related to the pathogenesis of eclampsia.
However, IUGR pathogenesis may be related to NO, not
to lipid peroxidation, in contrast to the pathology of
eclampsia.
The evidence indicates that NO can have either a prooxidant or an anti-oxidant effect on lipid peroxidation,
depending on a variety of contingent factors (22). At
relatively high concentrations, NO can attenuate
membrane dysfunction and tissue injury, while acting as a
reactive oxygene metabolite (23). On the other hand,
when generated at lower concentrations in the presence
of oxygen, superoxide and other reactive oxygen species,
NO can be converted into a range of potent oxidants (such
as nitrogen dioxide and peroxynitrite) which might
amplify and exacerbate the harmful effects of lipid
peroxidation (24).
Van Buren et al. (25) claimed that, NO might play a
role in uteroplacental blood circulation during pregnancy.
They said that treating sheep in the final stage of

pregnancy with NO synthetase inhibitors might cause a
decrease in uterine blood flow. Yallampalli and Garfield
(26), in their experiment, gave NO inhibitor to pregnant
rats, thus decreasing uterine blood flow, and investigated
foetal birth weights, finding significant growth
retardation. They claimed that this was due to
vasoconstriction in the placental vessels caused by a
decrease in NO release. Moreover, Di Iorio et al. (27)
suggested that in IUGR pregnancies a compensatory
increase in the synthesis of NO within the placenta might
occur in an attempt to maintain an adequate blood flow
through the placenta.
It seems that further experimental and clinical studies
are necessary to clarify the role of NO in IUGR pregnancy.
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Hatice PAfiAO⁄LU
Department of Biochemistry,
Faculty of Medicine, Gazi University,
Beflevler, Ankara - TURKEY

References
1.

2.

3.

4.

5.

92

Cunningham FG, MacDonald PC, Gant
NF et al. Hypertensive disorders of
pregnancy. Williams’ Obstetrics (Eds.
Cunningham FG, MacDonald PC, Gant
NF et al.) 19th ed. Norwalk,
Connecticut: Appleton & Lange. 1993,
pp: 763-817.
Goldenberg RL, Cutter GR, Hoffman HJ
et al. Intrauterine growth retardation;
Standards for diagnosis. Am J Obstet
Gynecol 161: 271-277, 1989.
Bates JA, Evans JA, Mason G.
Differentiation of growth retarded
from normally grown fetuses and
prediction of intrauterine growth
retardation using Doppler ultrasound.
Br J Obstet Gynecol 103: 670-675,
1996.

6.

Sladek SM, Magness RR, Conrad KP.
Nitric oxide and pregnancy. Am J
Physiol 272: 441-463, 1997.

7.

Seligman SP, Buyon JP, Clancy RM et
al. The role of nitric oxide in the
pathogenesis of preeclampsia. Am J
Obstet Gynecol 171: 944-948, 1994.

8.

9.

10.

Singh S, Evans TW. Nitric oxide the
biological mediator of the decade: Fact
or fiction? Eur Respir J 10: 699-707,
1997.
Narin F, Narin N, Paflao¤lu H et al.
Nitric oxide level in children with
pulmonary hypertension. Ind J Physiol
Pharmacol 44: 335-339, 2000.

11.

Smarason AK, Allman KG, Young O et
al. Elevated levels of serum nitrate, a
stable end product of nitric oxide, in
women with preeclampsia. Br J Obstet
Gynecol 104: 538-543, 1997.
Ranta V, Vionikka L, Halmesmaki E et
al. Nitric oxide production with
preeclampsia. Obstet & Gynecol 93:
442-445, 1999.
Davidge ST, Stranko CP, Roberts JM.
Urine but not plasma nitric oxide
metabolites are decreased in women
with preeclampsia. Am J Obstet
Gynecol 174: 1008-1013, 1996.
Silver RK, Kupfermine MJ, Russell TL
et al. Evaluation of nitric oxide as a
mediator of severe preeclampsia. Am J
Obstet Gynecol 175: 1013-1017,
1996.

12.

Maseki M, Nishigaki I, Hagihara M et al.
Lipid peroxide levels and lipid serum
content of serum lipoprotein fractions
of pregnant subjects with and without
preeclampsia. Clin Chim Acta 155: 155161, 1981.

13.

McLaughlin MK: Lipid peroxidation in
pregnancy: New perspectives on
preeclampsia. Am J Obstet Gynecol
161: 1025-1034, 1989.

14.

Curtis NE, Gudi NM, King RG et al.
Nitric oxide metabolites in normal
human pregnancy and preeclampsia.
Hypertens Pregnancy 14: 339-349,
1995.

15.

Hunter MIS, Nlemadim BC, Davidson
DLW. Lipid peroxidation products and
antioxidant proteins in plasma and
cerebrospinal fluids from multiple
sclerosis patients. Neurochem Res 10:
1645-1652, 1985.

16.

Wang Y, Walsh SW, Guo J et al. The
imbalance between thromboxane and
prostacyclin in preeclampsia is
associated with an imbalance between
lipid peroxides and vitamin E in
maternal blood. Am J Obstet Gynecol
165: 1695-1700, 1991.

H. PAfiAO⁄LU, N. BUKAN, G. BULDUK, fi. ÇELEN

17.

Pinto A, Sorrentino R, Sorrentino P et
al. Endothelial-derived relaxing factor
released by endothelial cells of human
umblical vessels and its impairment in
pregnancy-induced hypertension. Am J
Obstet Gynecol 164: 507-513, 1991.

21.

Creasy RK, Resnik R. Intrauterine
growth restriction, Creasy & Resnik
Maternal Fetal Medicine: Principles and
practice (Eds. RK. Creasy, R. Resnik)
W.B. Saunders Company, Philadelphia
1989, pp: 547-564.

25.

Van Buren GA, Yang D, Clark KE.
Estrogen-induced uterine vasodilatation
is antagonized by L- nitroarginine
methyl ester, an inhibitor of nitric oxide
synthesis. Am J Obstet Gynecol 167:
828-833, 1992.

18.

Davidge ST, Billiar TR, Roberts JM.
Plasma nitrites and nitrates, stable end
products of nitric oxide, are elevated in
women with preeclampsia. In:
Proceedings of the ninth international
congress of the International Society
for the Study of Hypertension in
Pregnancy. Sydney; Australia, March
15-18, 1994.

22.

Paternoster DM, Stella A, Mussap M et
al. Predictive markers of preeclampsia
in hypertensive disorders in pregnancy.
Int J Gynecol Obstet 66: 232-243,
1999.

26.

Yallampalli C, Garfield RE. Inhibition of
nitric oxide synthesis in rats during
pregnancy produces signs similar to
those of preeclampsia. Am J Obstet
Gynecol 169: 1316-1320, 1993.

23.

D’Ischia M, Palumbo A, Buzzo F.
Interactions of nitric oxide with lipid
peroxidation products under aerobic
conditions: inhibitory effects on the
formation of malondialdehyde and
related thiobarbituric acid-reactive
substances. Nitric Oxide: Biology and
Chemistry 4: 4-14, 2000.

27.

Di Iorio R, Marinoni E, Coacci F et al.
Amniotic fluid nitric oxide and
uteroplacental blood flow in pregnancy
complicated by intrauterine growth
retardation. Br J Obstet Gynecol 104:
1134-1139, 1997.

24.

O’Donnell VB, Chumley PH, Hogg N et
al. Nitric oxide inhibition of lipid
peroxidation: Kinetics of reaction with
lipid peroxyl radicals and comparison
with a-tocopherol. Biochem 36:
15216-15523, 1997.

19

Norris LA, Higgins JR, Darling MRN et
al. Nitric oxide in the uteroplacental,
fetoplacental and peripheral circulations
in preeclampsia. Obs & Gyn 93: 958963, 1999.

20.

Zeeman CG, Dekkar GA, Van Geijn HP
et al. Endothelial function in normal and
preeclamptic pregnancy: A hypothesis.
Eur J Obstet Gynecol Reprod Biol 43:
113-122, 1992.

93

